ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration

Breast cancer (BRCA) has traditionally been considered as having poor immunogenicity and is characterized by relatively low tumor mutational burden (TMB). Improving immunogenicity may improve the response to clinical immunotherapy of BRCA. However, the relationship between TMB, immune infiltration,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jia, Zhang, Xiaolu, Li, Jie, Ma, Xiaoran, Feng, Fubin, Liu, Lijuan, Wu, Jibiao, Sun, Changgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835009/
https://www.ncbi.nlm.nih.gov/pubmed/33234738
http://dx.doi.org/10.18632/aging.104204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835009/
https://www.ncbi.nlm.nih.gov/pubmed/33234738
http://dx.doi.org/10.18632/aging.104204

Ejemplares similares